An update on oral contraceptive options

Formulary

Volumn 39, Issue 2, 2004, Pages 104-121

  Edwards, Lisa A ^a  

^a Blue Cross Blue Shield of Rhode Island   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLESSA; DEMULEN 1-35; DEMULEN 1-50; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROSTEP 21; ESTROSTEP FE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETONOGESTREL; ETYNODIOL DIACETATE; GESTAGEN; LEVONORGESTREL; LOESTRIN 21 1-20; LOESTRIN 21 1.5-30; LOESTRIN FE 1-20; LOESTRIN FE 1.5-30; MEDROXYPROGESTERONE ACETATE; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; ORTHO MICRONOR; ORTHO NOVUM 10-11; ORTHO TRICYCLEN LO; OVCON 35 CHEWABLE; OVCON 50; POTASSIUM SPARING DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; AMENORRHEA; BLOOD CLOTTING; BREAKTHROUGH BLEEDING; BREAST CANCER; BREAST TUMOR; BREATHING DISORDER; CEREBROVASCULAR DISEASE; CHLOASMA; CLINICAL TRIAL; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; ECTOPIC PREGNANCY; EDEMA; EYE DISEASE; FATIGUE; FLUID RETENTION; GALLBLADDER DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART INFARCTION; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; INCREASED APPETITE; IRRITABILITY; JAUNDICE; LEG PAIN; LEUKORRHEA; LIBIDO DISORDER; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MIGRAINE; MOOD DISORDER; NAUSEA; NERVOUSNESS; ORAL CONTRACEPTION; PARESTHESIA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPEECH DISORDER; SPOTTING; STROKE; TELANGIECTASIA; TENSION HEADACHE; THORAX PAIN; THROMBOEMBOLISM; UTERINE CERVIX CANCER; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN;

EID: 1242293834     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Gladwell M. John Rock's error. The New Yorker. March 13, 2000:52-63.
2. Junod SW. FDA's approval of the first oral contraceptive, Enovid. Available at: http://www.fda.gov/ oc/history/makinghistory/enovid.html. Accessed November 12, 2003.
3. Snider S. The Pill: 30 years of safety concerns. Available at: http://www.fda.gov/bbs/topics/ consumer/con00027.html. Accessed November 12, 2003.
4. Petitti DB. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349: 1443-1450.
5. Bucci KK, Carson DS. Contraception in DiPiro JT, Talbert RL (eds): Pharmacotherapy 3rd ed, Stamford, Conn: Appleton and Lange; 1997: 1601-1620.
6. Hatcher RA, Nelson AL, Zieman M, et al. A pocket guide to managing contraception. 2003-2004 ed. Tiger, Ga: The Bridging the Gap Foundation; 2003:91-118. Available at: http://www.managing contraception.com. Accessed November 12, 2003.
7. Kaunitz AM. Menstruation: choosing whether...and when. Contraception. 2000;62:277-284.
8. Petitti DB. Supplement to combination estrogen-progestin oral contraceptives. N Engl J Med. 2003; 349:1443-1450 (supplementary Appendix 1).
9. Hansen LB. Oral contraceptives: An update on health benefits and risks. J Am Pharm Assoc. 2001;41:875-886.
10. Killion KH, Kastrup EK, eds. Drug Facts and Comparisons. St. Louis, Mo: Facts and Comparisons: Wolters Kluwer Health, Inc.; 2003:234c-245c.
11. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
12. Yasmin (drospirenone and ethinyl estradiol) [Package Insert]. Wayne, NJ: Berlex Laboratories; November 2001.
13. Jolly J. New age of contraceptives. Drug Facts and Comparisons NEWS. November 2003;83-85.
14. Fuller S. Are all contraceptives created equally? US Pharmacist. 1997;22(9): Available at: http://www.uspharmacist.com.
15. Labeling guidance text for progestin-only oral contraceptives prescribing information professional labeling, revised May 1995. Available at: http://www.fda.gov/medwatch/safety/label/ guidance.htm. Accessed January 17, 2004.
16. Hatcher RA, Guillebaud J. The pill: combined oral contraceptives. In: Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology, New York, NY: Ardent Media; 1998:405-466.
17. Davidson NE, Helzsouer KJ. Good news about oral contraceptives. N Engl J Med. 2002;346: 2078-2079.
18. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral-contracpetive use and the risk of breast cancer. N Engl J Med. 1986;315:405-411.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996; 347:1713-1727.
20. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ. 1999; 318:1579-1584.
21. Pymar HC, Creinin MD. The risks of oral contraceptive pills. Semin Reprod Med. 2001; 19:305-312.
22. Goldbaum GM, Kendrick JS, Hogelin GC, et al. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA. 1987;258:1339-1342.
23. Petitti DB, Sidney S, Bernstein A et al. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8-15.
24. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 2000;284:72-78.
25. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49-52.
26. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-1535.
27. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312:83-88.
28. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis:meta-analysis. BMJ. 2001;323:1-9.
29. O'Brien P. The third generation oral contraceptive controversy. BMJ. 1999;319:795-796.
30. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085-1092.
31. Smith JS, Green J, de Gonzalez AB, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159-1167.
32. Fraser IS, Kovacs GT. The efficacy of non-contraceptive uses for hormonal contraceptives. Med J Aust. 2003;178:621-623.
33. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266.
34. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial. Obstet Gynecol. 2003; 101:653-661.
35. Sucato GS, Gold MA. Tips for clinicians: Extended cycling of oral contraceptive pills for adolescents. J Pediatr Adolesc Gynecol. 2002;15: 325-327.
36. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142-1149.
37. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low dose oral contraceptive: a randomized trial. Contraception. 2003;67:9-13.
38. Seasonale (levonorgestrel/ethinyl estradiol) [Package Insert]. Pomona, NY: Duramed Pharmaceuticals, Inc, a subsidiary of Barr Laboratories Inc; September 2003.
39. Anderson FD, Hait H, Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89-96.
40. Grant ECG. Dangers of suppressing menstruation. Lancet. 2000;356:513.
41. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet. 2000;355:922-924.
42. Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. A word of caution about protection. JAMA. 1985; 253:2246-2250.
43. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233-241.
44. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235-240.
45. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA. 249; 1600-1604.
46. Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med. 1998;43:286-290.
47. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, et al., Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999;60:255-262.
48. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol. 2003;188:1158-1160.
49. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception. 2000;61:77-82.
50. Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: A case-control study. Lancet. 1999;353:1481-1484.
51. Ortho Tri-Cyclen, Ortho-Cyclen (norgestimate/ethinyl estradiol) [Package Inserts]. Raritan, NJ: Ortho-McNeil Pharmaceuticals, Inc; March 2001.
52. News Release: FDA approval for new form of Galen drug. Financial Times Information Limited-European Intelligence Wire. November 18, 2003. Available at: www.pharmacyonesource.com. Accessed November 24, 2003.
53. F-D-C Reports, Inc. Watson inventory reserves reflect delayed launch of Wellbutrin SR generics. "The Pink Sheet" November 10, 2003.65(45):21.
54. Electronic Orange Book: Approved drug products with therapeutic equivalents evaluations. Available at: http://www.fda.gov/cder/ob/. Accessed February 3, 2004.
55. Medispan. Master Drug Database. (pricing software). Wolters Kluwer Health, Inc. Updated Bimonthly. Accessed December 4, 2003.
56. Barr Labs press release. Barr launches generic version of Ortho Tri-Cyclen tablets. December 29,2003. Available at: http://www.barrlabs.com/ pages/nprpr.html. Accessed January 17, 2004.
57. Watson Pharmaceuticals press release. Watson Pharmaceuticals launches Tri-Nessa oral contraceptive. December 29, 2003. Available at: http://www.corporate-ir.net/ireye/ir_site.zhtml? ticker=WPI&script=410& layout=6&item_id=480 538. Accessed January 17, 2004.
58. Chambers KH. Enhancing quality of life with today's hormonal contraceptives. In: Power-Pak CE. New York, NY; 2003.
59. Heaton AH. The managed care pharmacy perspective. Am J Manag Care. 2001;7(18 Suppl): S567-S570.
60. The Alan Guttmacher Institute. The cost of contraceptive insurance coverage. Issues in brief. New York, NY; 2003 Series, No.4. Available at: http://www.guttmacher.org. Accessed December 4, 2003.